COMPASS Pathways’ sole asset, COMP360, has met its primary endpoint Phase IIb trial in treatment-resistant depression (TRD), albeit racking up serious adverse events along the way.
Nonetheless, given the lack of alternative treatments, the data indicate a clear role for psilocybin-based candidates in patients who do
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?